Histopathology of Basal Cell Carcinoma After Treatment With Vismogedib

Jennifer C. Tang, Larry Buckel, C. William Hanke

Research output: Contribution to journalArticlepeer-review


Background: Vismodegib used in the treatment of metastatic basal cell carcinoma (BCC) or locally advanced, recurrent BCC not amenable to surgery or radiation leads to various clinical changes. Objective: Aim was to elucidate the histopathology that corresponds to tumor involution observed with vismodegib therapy. Methods: Retrospective case series of patients treated with vismodegib between May 2012 and April 2017 with intra- or post-treatment biopsy. Results: 42 biopsy specimens and 4 Mohs frozen sections were analyzed. Necrosis, fibrosis, and increased plasma cells were common features. Limitations: Single center study. Conclusion: The histologic findings of BCCs treated with vismodegib correlate with clinical response. J Drugs Dermatol. 2019;18(2):136-138.

Original languageEnglish (US)
Pages (from-to)136-138
Number of pages3
JournalJournal of drugs in dermatology : JDD
Issue number2
StatePublished - Feb 1 2019
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Histopathology of Basal Cell Carcinoma After Treatment With Vismogedib'. Together they form a unique fingerprint.

Cite this